Peptide education
Calcitonin salmon
Salmon calcitonin · Miacalcin
Calcitonin salmon is a synthetic version of a hormone found in salmon. It slows the activity of cells that break down bone. U.S. prescription products include a nasal spray and an injection, with different uses and doses.
Calcitonin salmon has several prescription uses, but its formulations are not interchangeable. Both U.S. labels say fracture-reduction efficacy has not been demonstrated, even though one nasal-spray trial reported fewer vertebral fractures.
Overview
Quick answer
The nasal spray is labeled for selected women with postmenopausal osteoporosis. The injection also has indications for selected symptomatic Paget's disease and the early treatment of hypercalcemic emergencies. The spray is not the labeled product for those injection-specific uses.
When is the nasal spray used?
The U.S. nasal label covers osteoporosis in women more than five years past menopause when alternative treatments are unsuitable. It states that fracture-reduction efficacy has not been demonstrated.
What does the injection treat?
The injection is labeled for selected symptomatic Paget's disease, early treatment of hypercalcemic emergencies alongside other appropriate treatments, and selected postmenopausal osteoporosis patients.
What did the nasal-spray fracture trial report?
In PROOF, 51 of 287 women receiving 200 IU daily and 70 of 270 receiving placebo had a new vertebral fracture in the reported analysis. The publication reported a relative risk of 0.67. The U.S. nasal label still states that fracture-reduction efficacy has not been demonstrated.
Why might treatment be reassessed?
The labels describe a possible association with malignancy and call for periodic review of whether treatment should continue. They also warn about allergic reactions and low blood calcium.
Evidence
Evidence snapshot
The spray label restricts use to women more than five years past menopause when alternatives are unsuitable.
The publication reported fewer new vertebral fractures with 200 IU daily than with placebo, but completion was limited.
Both cited product labels state that fracture-reduction efficacy has not been demonstrated.
The injection label includes selected symptomatic Paget's disease and early treatment of hypercalcemic emergencies.
Claims
Common claims vs evidence
| Claim | Human evidence | Verdict |
|---|---|---|
| The nasal spray reduces vertebral fractures. | PROOF randomized 1,255 women with established osteoporosis to nasal calcitonin or placebo. The 200 IU group had a lower reported rate of new vertebral fracture than placebo. Only 511 participants completed five years, and the 100 IU and 400 IU groups did not differ significantly from placebo. | The trial reported a specific finding, but the current U.S. spray label says fracture-reduction efficacy has not been demonstrated. |
| The spray and injection have the same uses. | The U.S. injection label includes early treatment of hypercalcemic emergencies and selected symptomatic Paget's disease. The nasal-spray label covers selected postmenopausal osteoporosis patients, not those injection uses. | The products have different indications and dosing instructions. |
| Calcitonin salmon may be associated with an increased risk of cancer. | The label describes higher overall malignancy incidence in a pooled analysis of randomized trials of nasal or investigational oral calcitonin compared with placebo. The injection routes were not studied in that pooled analysis. | The finding raises a safety concern, not a prediction for an individual. The injection label says an increased risk with injection cannot be excluded. |
Bottom line
Main takeaway
The same ingredient name appears on a nasal spray and an injection, but the medical uses differ.
The labels reserve osteoporosis use for selected patients when alternatives are unsuitable and do not establish fracture-reduction efficacy.
Compare the PROOF publication's endpoint and completion rate with the separate fracture-efficacy statement in the U.S. nasal label.
Identity
What it is
Calcitonin salmon is a 32-amino-acid peptide that acts on calcitonin receptors and inhibits bone resorption.
The injection is administered under the skin or into muscle; the nasal product is a metered spray.
Use context
Routes, doses, and cycle patterns
The formulation and clinical condition determine the labeled route and dose.
Human studies and product labels
Nasal spray label
- Purpose
- Selected postmenopausal osteoporosis
- Context
- U.S. prescription label
- Route
- Intranasal
- Amount
- 200 IU, one spray
- Frequency
- Once daily, alternating nostrils
The label specifies women more than five years past menopause for whom alternatives are unsuitable.
Injection label for symptomatic Paget's disease
- Purpose
- Selected patients with moderate to severe symptomatic disease
- Context
- U.S. prescription label
- Route
- Subcutaneous or intramuscular
- Amount
- 100 IU
- Frequency
- Once daily
The label describes moderate to severe disease involving multiple bones, with elevated serum alkaline phosphatase and urinary hydroxyproline. It reserves use for patients who do not respond to alternatives or for whom alternatives are unsuitable.
Injection label for hypercalcemic emergencies
- Purpose
- Early calcium lowering alongside other appropriate treatment
- Context
- U.S. prescription label
- Route
- Subcutaneous or intramuscular
- Amount
- Starting dose 4 IU per kg of body weight
- Frequency
- Every 12 hours initially
The label describes subsequent dose changes according to response in the emergency setting.
PROOF trial
- Purpose
- Vertebral fractures in postmenopausal osteoporosis
- Context
- Published study regimen
- Route
- Intranasal
- Amount
- Separate 100, 200, and 400 IU groups
- Frequency
- Once daily
- Duration
- Five-year study
The 200 IU group was the primary fracture comparison with placebo.
What varies
- The injection label also lists 100 IU daily under the skin or into muscle for selected postmenopausal osteoporosis patients.
- Calcium and vitamin D intake should be assessed in osteoporosis treatment; the individual product label supplies its instructions.
Research
Research evidence
PROOF assessed nasal spray in postmenopausal osteoporosis. The U.S. labels separately describe the approved formulations and their limits.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| PROOF | 1,255 postmenopausal women with established osteoporosis | Randomized, double-blind, placebo-controlled | Nasal spray at 100, 200, or 400 IU daily | Published vertebral-fracture risk was lower with 200 IU than placebo | 511 participants completed five years; the other doses did not show a significant fracture reduction | Study result differs from the U.S. label's fracture-efficacy conclusion |
| Injection prescribing information | Patients meeting each labeled indication | U.S. product label and clinical-study summary | Subcutaneous or intramuscular injection | Separate indications for selected Paget's disease and early treatment of hypercalcemic emergencies | The label says osteoporosis fracture-reduction efficacy has not been demonstrated | Product and indication context |
Cautions
Safety and unknowns
- The nasal and injection labels contraindicate use in people with known hypersensitivity to calcitonin salmon or any product ingredient.
- Serious allergic reactions can occur. Swelling of the face or throat or trouble breathing requires urgent medical attention.
- Calcitonin can lower blood calcium. The labels advise correcting pre-existing hypocalcemia and assessing calcium and vitamin D intake where applicable.
- Nasal irritation and nosebleeds can occur with the spray. The labels describe a possible malignancy association and recommend periodic reassessment of continued use.
Product quality
Product identity and quality
The nasal spray and injection use different delivery devices and labeling. Their directions should not be exchanged.
Formulation
The nasal and injection labels do not cover the same indications.
Strength and route
International-unit doses and administration routes vary by product and indication.
Mechanism
How it is proposed to work
Calcitonin reduces the activity of bone-resorbing cells, which can reduce the release of calcium from bone.
Calcitonin salmon acts through calcitonin receptors; the injection label describes rapid calcium lowering in hypercalcemic emergencies.
FAQ
Common questions
Can the nasal spray be used for a hypercalcemic emergency?
The cited U.S. nasal label does not include that indication. The injection label describes early treatment of hypercalcemic emergencies alongside other appropriate treatment.
Details
Technical details
Sources
References
- 1.
DailyMed. Calcitonin salmon nasal spray prescribing information
U.S. nasal-spray indication, dose, safety, and fracture-evidence limitation.
- 2.
DailyMed. Calcitonin salmon injection prescribing information
U.S. injection indications, dosing by indication, and safety.
- 3.
DailyMed. Miacalcin injection prescribing information
Product-specific label for the Miacalcin injection name.
- 4.
doi:10.1016/S0002-9343(00)00490-3 PMID:10996576
PROOF trial of nasal calcitonin and vertebral fractures; interpretation is distinct from the U.S. product label.